Ovarian Cancer

BMS-247550 is a methyl, semi-synthetic analog of the natural product epothilone B. Provided to the National Cancer Institute (NCI) by Bristol-Myers Squibb, BMS-247550 was chosen for clinical development because it demonstrated

Advances in molecular virology and biotechnology have led to the engineering of vectors that can efficiently transfer genes to target cells. Gene therapy strategies were developed along two lines: Cytotoxic approaches

In part I of this series, we identified currently active clinical trials that include health-related quality-of-life (HRQOL) outcomes as a primary or secondary objective of the overall study (Trimble EL et al: ONCOLOGY 15:601-611, 2001). The goal of this

Advances in molecular virology and biotechnology have led to the engineering of vectors that can efficiently transfer genes to target cells. Gene therapy strategies were developed along two lines: Cytotoxic approaches

HOUSTON, Texas-David M. Gershenson, MD, painted a bleak picture of current treatment for advanced ovarian cancer and suggested that new agents such as topoisomerase inhibitors should be studied further in clinical trials. Dr. Gershenson said that although CA-125 and transvaginal ultrasound are used for screening, they have limited efficacy, with the result that over 70% of ovarian cancers have already spread beyond the ovary by the time they are detected.

Promising interim results of a double-blind placebo-controlled trial of the monoclonal antibody OvaRex in 345 patients with

At the 37th annual meeting of the American Society of Clinical Oncology, investigators from the Scottish Gynaecologic

SAN FRANCISCO-More than four out of 10 cancer patients received chemotherapy during their last year of life, according to a study of Medicare patients in Massachusetts. Even a proportion of patients with tumors considered unresponsive to chemotherapy received treatments within 1 month of their death.

SAN FRANCISCO-Preliminary data from an uncontrolled pilot study suggest that levocarnitine (L-Carnitine, Carnitor) supplementation can reduce fatigue in some patients. Francesco Graziano, MD, found that 87% of patients given levocarnitine 4 g/day po for 7 days reported reduced fatigue. Dr. Graziano is in the medical oncology department at the Hospital of Urbino, Italy.

SAN FRANCISCO-Amifostine (Ethyol) provided cytoprotection and allowed the maximum tolerated dose of melphalan (Alkeran) to be increased to 280 mg/m2 for cancer patients receiving autologous hematopoietic stem cell transplantation in a phase I and II study. Dose-limiting toxicity of melphalan was not able to be clearly determined from the trial, however, and might be higher, according to Gordon L. Phillips II, MD, director of the bone marrow transplantation program of the Greenebaum Cancer Center at the University of Maryland in Baltimore.

Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities

Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities

Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities

Assessing the risk of breast and ovarian cancer starts with obtaining a complete and accurate family history. This can reveal evidence of inherited cancer risk. The highest risk of cancer is associated with germ-line abnormalities

Irinotecan (CPT-11, Camptosar) is a camptothecin derivative thatis thought to exert its cytotoxic effects by targeting topoisomerase

With the understanding of the mechanism of malignant transformation has come the knowledge that oncogene products are frequently growth factors, growth factor receptors, or elements of growth factor signal-transduction pathways. Overexpression

Combination chemotherapy with carboplatin (Paraplatin) and docetaxel (Taxotere) is a highly active and generally well-tolerated regimen when used as initial therapy for gynecologic cancers, including cancers of the ovary, fallopian tubes, and the

The Clinical Trials Referral Resource that appeared in the April issue of ONCOLOGY began a series on health-related quality of life (HRQOL). Part I of this series, which concludes this month, focuses on HRQOL questions in cancer treatment trials. Part II (on investigator-initiated HRQOL research) and part III (on HRQOL research as part of cancer prevention trials) will appear in upcoming issues. Information about these studies can be obtained from the contacts listed for each trial or from Edward L. Trimble, MD, MPH, at the Cancer Therapy Evaluation Program (CTEP), trimble@ctep.nci.nih.gov or (301) 496-1196

NEW YORK-In a phase I/II study combining gemcitabine (Gemzar) and oxaliplatin, French investigators saw a 47% objective response rate among evaluable patients with advanced non-small-cell lung cancer (NSCLC).

HOUSTON-New studies of irinotecan-based regimens for gynecologic cancers were reviewed by Andrzej P. Kudelka, MD, and Claire Verschaegen, MD. He is associate professor and she is an assistant professor in the Division of Cancer Medicine at the University of Texas M.D. Anderson Cancer Center in Houston.

NASHVILLE-Long-term aspirin use may decrease the risk of epithelial ovarian cancer, Arslan Akhmedkhanov, MD, reported at the 32nd Annual Meeting of the Society of Gynecologic Oncologists (SGO). The study involved 748 patients from a prospective cohort followed for an average of 12 years.

WASHINGTON-Cigarette smoking has inflicted an enormous toll on American women during the last two decades, according to the latest Surgeon General’s report. "The single overarching theme emerging from this report is that smoking is a women’s issue," said Surgeon General David Satcher, MD.

NEW YORK-Irofulven, the first of the acylfulvenes, a new class of cytotoxic agents, is being studied in a number of solid tumors, including a phase III trial in advanced pancreatic cancer, said Raymond Taetle, MD, clinical professor of medicine and pathology, University of Arizona, Arizona Cancer Center, Tucson.

The diagnosis and management of cancer in older women is becoming an increasingly common and challenging issue. Women who reach age 65 can expect to live an additional 17 years.[1] Age is an important risk factor for developing cancer. Epidemiologic data from 1992 to 1994 reveal that invasive cancer develops in 1 of 5 women aged 60 to 79 years.[2]

The aging population poses new challenges to all fields of medicine and to gynecologic oncology in particular. In gynecologic oncology, issues that are germane to general medicine, cancer chemotherapy, radical surgery, and routine gynecology are all encountered on a regular basis. In clinical practice, the "very old" are often thought to tolerate standard treatments poorly. While comorbid conditions may be more prevalent, management decisions should be based on an assessment of individual function and not solely on numerical age. In the article by Mirhashemi and colleagues, this theme is conveyed throughout, as they describe the current management of gynecologic malignancies in older women.